Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
The RESILIENT-Extend trial showed benefit for thrombectomy in the 8- to 24-hour window without the need for costly imaging equipment, albeit with some caveats.
Scientists in Brazil conducted a trial to examine whether laughter therapy can improve cardiovascular symptoms. It looked at adults who had all been diagnosed with coronary artery disease.